ELISA Kit for Insulin Like Growth Factor 1 (IGF1)

0.156-10ng/mL

The minimum detectable dose of this kit is typically less than 0.067ng/mL

3h

This assay has high sensitivity and excellent specificity for detection of Insulin Like Growth Factor 1 (IGF1).
No significant cross-reactivity or interference between Insulin Like Growth Factor 1 (IGF1) and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Insulin Like Growth Factor 1 (IGF1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Insulin Like Growth Factor 1 (IGF1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Insulin Like Growth Factor 1 (IGF1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Insulin Like Growth Factor 1 (IGF1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

A Combinatorial Relative Mass Value Evaluation of Endogenous Bioactive Proteins in Three-Dimensional Cultured Nucleus Pulposus Cells of Herniated Intervertebral Discs: Identification of Potential Target Proteins for Gene Therapeutic Approaches; Porcine follicular fluid concentration of free insulin-like growth factor-I collected from different diameter ovarian follicles; EVALUATION OF PHYSICO-CHEMICAL PROPERTIES OF COLOSTRUM SUPPLEMENTED DAHI; Electrochemical immunosensor for the determination of insulin-like growth factor-1 using electrodes modified with carbon nanotubes–poly(pyrrole propionic acid) hybrids; A Pilot Study Comparing the Effect of Flaxseed, Aromatase Inhibitor, and the Combination on Breast Tumor Biomarkers; The effects of self-assembling peptide RADA16 hydrogel on malignant phenotype of human hepatocellular carcinoma cell; Effects of acute exercise on salivary free insulin-like growth factor 1 and interleukin 10 in sportsmen.; Assessment of feeding varying levels of Metabolizable energy and protein on performance of transition Murrah buffaloes; A DPP-IV-resistant glucagon-like peptide-2 dimer with enhanced activity against radiation-induced intestinal injury; Effect of dietary protein intake on the body composition and metabolic parameters of neutered dogs; Dietary supplementation for Santa Inês hair ewes on pasture at pre-and postpartum periods: dry matter intake, digestibility, milk production, and mineral metabolism; The therapeutic effects of nicotinamide in hepatocellular carcinoma through blocking IGF-1 and effecting the balance between Nrf2 and PKB;